Add to ORKGAntifibrinolytic agents in traumatic haemorrhage: A large-scale randomised controlled trial is neede
Background: Trauma is a global disease, with over 2.5 million deaths annually from hemorrhage and co...
Background: There is increasing interest in the timely administration of concentrated sources of fib...
INTRODUCTION: Worldwide, trauma is a leading cause of death and disability. Haemorrhage is responsib...
This article is an invitation to doctors around the world to participate in the CRASH-2 trial (Clini...
For people at ages 5 to 45 years, trauma is second only to HIV/AIDS as a cause of death. Each year, ...
Every year, more than a million people die as a result of trauma. This huge mortality could be parti...
In South Africa, trauma is a major concern, with violence and road traffic accidents being the fifth...
Hemorrhagic shock and death from exsanguination remain common following traumatic injury. Attaining ...
A large randomised placebo controlled trial among trauma patients with or at risk of significant hae...
Background: Haemorrhage is a leading cause of death in severe trauma. Fibrinogen plays a critical ro...
This editorial is an open invitation to trauma doctors to participate in the international CRASH-2 t...
Background: The Ben Taub General Hospital (BTGH) is one of the largest level I trauma centers in the...
There is a growing interest in the role that fibrinogen plays in major haemorrhage. It has been know...
In this research agenda on the acute and critical care management of trauma patients, we concentrate...
Background: The Clinical Randomisation of an Anti-fibrinolytic in Significant Hemorrhage-2 (CRASH-2)...
Background: Trauma is a global disease, with over 2.5 million deaths annually from hemorrhage and co...
Background: There is increasing interest in the timely administration of concentrated sources of fib...
INTRODUCTION: Worldwide, trauma is a leading cause of death and disability. Haemorrhage is responsib...
This article is an invitation to doctors around the world to participate in the CRASH-2 trial (Clini...
For people at ages 5 to 45 years, trauma is second only to HIV/AIDS as a cause of death. Each year, ...
Every year, more than a million people die as a result of trauma. This huge mortality could be parti...
In South Africa, trauma is a major concern, with violence and road traffic accidents being the fifth...
Hemorrhagic shock and death from exsanguination remain common following traumatic injury. Attaining ...
A large randomised placebo controlled trial among trauma patients with or at risk of significant hae...
Background: Haemorrhage is a leading cause of death in severe trauma. Fibrinogen plays a critical ro...
This editorial is an open invitation to trauma doctors to participate in the international CRASH-2 t...
Background: The Ben Taub General Hospital (BTGH) is one of the largest level I trauma centers in the...
There is a growing interest in the role that fibrinogen plays in major haemorrhage. It has been know...
In this research agenda on the acute and critical care management of trauma patients, we concentrate...
Background: The Clinical Randomisation of an Anti-fibrinolytic in Significant Hemorrhage-2 (CRASH-2)...
Background: Trauma is a global disease, with over 2.5 million deaths annually from hemorrhage and co...
Background: There is increasing interest in the timely administration of concentrated sources of fib...
INTRODUCTION: Worldwide, trauma is a leading cause of death and disability. Haemorrhage is responsib...
